Truist analyst David MacDonald downgraded Molina Healthcare (MOH) to Hold from Buy with a price target of $180, down from $335. The company’s Q2 results and reduced outlook were impacted by accelerating medical cost pressures across all business lines, the analyst tells investors in a research note. The firm cites the challenging medical cost trend environment for the downgrade.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOH:
- Molina Healthcare price target lowered to $186 from $270 at Barclays
- Molina Healthcare price target lowered to $179 from $373 at Baird
- Cantor downgrades Molina to Neutral on Medicaid uncertainty
- Molina Healthcare Reports Q2 2025 Financial Results
- Molina Healthcare Earnings Call: Mixed Sentiment Amid Growth